Artios
DNA Damage Response | DDR Company | Artios Pharma
Cambridge, United Kingdom · Founded 2016 · $115.0M raised
- Headquarters
- Cambridge
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- artios.com
- Total Funding
- $115.0M
- Last Round
- $115.0M Series DNov 2025
- Rounds
- 1
About
Artios is a clinical-stage biopharmaceutical company focused on developing cancer therapies that target the DNA Damage Response pathway. Based at the Babraham Campus in Cambridge, UK, it has built a pipeline of DDR inhibitors including alnodesertib (ATR inhibitor) and a Pol Theta inhibitor program. Co-founded in 2016 by pioneering DDR researchers, Artios raised $115M in a Series D in 2025.
Summary
Artios is a Biotech company based in Cambridge, United Kingdom, founded in 2016. It has raised $115.0M in total across 1 round, most recently a $115.0M Series D round in Nov 2025.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2025
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company